Edition:
United Kingdom

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,976.00GBp
20 Apr 2018
Change (% chg)

20.50 (+0.41%)
Prev Close
4,955.50
Open
4,971.50
Day's High
4,986.50
Day's Low
4,960.00
Volume
1,448,352
Avg. Vol
2,105,655
52-wk High
5,585.07
52-wk Low
4,260.00

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £65,514.78
Shares Outstanding(Mil.): 1,265.91
Dividend: 68.90
Yield (%): --

Financials

  AZN.L Industry Sector
P/E (TTM): 22.12 30.95 32.74
EPS (TTM): 2.34 -- --
ROI: 7.86 14.84 14.38
ROE: 28.47 16.34 16.07

AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug

U.S. regulators have expanded use of AstraZeneca's lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday.

19 Apr 2018

UPDATE 1-AstraZeneca wins U.S. approval for 1st-line use of lung cancer drug

April 18 U.S. regulators have expanded use of AstraZeneca's lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday.

19 Apr 2018

AstraZeneca wins U.S. FDA approval for 1st-line use of lung cancer drug

April 18 AstraZeneca Plc said on Wednesday the U.S. Food and Drug Administration (FDA) has approved the 1st-line use of its lung cancer drug, Tagrisso.

19 Apr 2018

BRIEF-Highmark Inc Signs Outcomes-Based Agreement With Astrazeneca For Symbicort

* HIGHMARK INC. SIGNS OUTCOMES-BASED AGREEMENT WITH ASTRAZENECA FOR SYMBICORT Source text for Eikon: Further company coverage:

17 Apr 2018

BRIEF-AstraZeneca Updates On Overall Survival Data For Lynparza Presented At AACR

* UPDATED OVERALL SURVIVAL DATA FOR LYNPARZA IN BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER PRESENTED AT AACR

16 Apr 2018

BRIEF-Molecular Partners To Cooperate With Astrazeneca On Ongoing Oncology Clinical Study

* ANNOUNCES COLLABORATION WITH ASTRAZENECA ON ONGOING ONCOLOGY CLINICAL STUDY WITH MP0250 IN EGFR-MUTATED NSCLC Source text for Eikon: Further company coverage: (Gdynia Newsroom)

11 Apr 2018

Ionis may get up to $300 million in licensing deal with AstraZeneca

Ionis Pharmaceuticals Inc said on Monday a licensing deal for its fatty liver disease treatment with AstraZeneca Plc could fetch up to $300 million in milestone payments.

09 Apr 2018

UPDATE 1-Ionis may get up to $300 mln in licensing deal with AstraZeneca

April 9 Ionis Pharmaceuticals Inc said on Monday a licensing deal for its fatty liver disease treatment with AstraZeneca Plc could fetch up to $300 million in milestone payments.

09 Apr 2018

Ionis to get up to $300 mln from licensing deal with AstraZeneca

April 9 Ionis Pharmaceuticals said on Monday it signed a licensing deal for its fatty liver disease treatment with AstraZeneca Plc that could land the company up to $300 million in milestone payments and royalties.

09 Apr 2018

BRIEF-Ionis And AstraZeneca Advance New Drug For NASH

* IONIS PHARMACEUTICALS INC - EARNS $30 MLN LICENSE FEE FOR IONIS-AZ6-2.5-L RX

09 Apr 2018

Earnings vs. Estimates